Hit enter to search or ESC to close
With a share price rally of 42.8% year-to-date, ST Engineering (SGX:S63) is now the Straits Times Index’s top performer. Behind the gains is a story of strategic transformation, smart positioning amid global defence rearmament,...
Two of Asia’s leading property trusts—Frasers Centrepoint Trust (FCT) and CapitaLand India Trust (CLINT)—are making bold strategic plays to shape the future of retail and digital infrastructure across the region. While FCT is betting...
In a tale of two electric vehicle (EV) giants, Tesla and BYD are locked in a global battle for dominance — and while Ark Invest’s Cathie Wood remains staunchly bullish on Tesla’s future, China’s...
The FTSE REIT Index is testing a well-established resistance at 633, and momentum may finally be tilting toward a breakout. Analysts note that both short- and medium-term indicators have strengthened, but caution that the...
Seatrium (STM SP): Well-positioned To Take Advantage Of Growth Opportunities UOB Kay Hian | 21 March 2025 Seatrium’s Competitive Position Remains Strong Seatrium’s competitive position in Brazil remains strong, and the company is well-positioned...
Hongkong Land (HKL) has made a landmark commitment to China, unveiling West Bund Central in Shanghai — the group’s largest single investment to date, valued at US$11.5 billion. While HKL has traditionally been associated...
Lim Seong Hai Capital Berhad (LSH Capital) IPO Purpose of IPO: LSH Capital aims to raise RM168.08 million through its IPO to fund business expansion, repay bank borrowings, and for working capital. The...
Visen Pharmaceuticals, a biopharmaceutical company specializing in endocrinology treatments in China, is set to list on the Hong Kong Stock Exchange under the ticker 02561.HK. The IPO is scheduled for March 21, 2025, aiming...
Sustainable Growth In Singapore; Green Shoots In China Keppel DC REIT (KDCREIT SP) Broker: UOB Kay Hian Date of Report: 20 March 2025 Keppel DC REIT (KDCREIT), the first pure-play data centre REIT in...
Value Partners is making a compelling argument for why quality China A-shares may present significant upside potential, citing two major factors: deep undervaluation and Beijing’s push for a “value-up” strategy. The firm’s proprietary Free...
